Structure via PubChem · Public domain (PubChem)
cidofovir
Sign in to saveAlso known as GS-0504, 1-(S)-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine, CDV, (S)-1-[3-Hydroxy-2-(phosphonylmethoxy)propyl]cytosine, [(S)-2-(4-Amino-2-oxo-2H-pyrimidin-1-yl)-1-hydroxymethyl-ethoxymethyl]-phosphonic acid, (S)-1-[3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine, (S)-(3-(4-amino-2-Oxopyrimidin-1(2H)-yl)-1-hydroxypropan-2-yloxy)methylphosphonic acid, (S)-1-(3-Hydroxy-2-phosphonomethoxypropyl)cytosine
Cidofovir, brand name Vistide, is a topical or injectable antiviral medication primarily used as a treatment for cytomegalovirus (CMV) retinitis (an infection of the retina of the eye) in people with AIDS.
Key facts
- Drug.verifiedrevid
- 477165826
- Drug.IUPAC_name
- ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid
- Drug.image
- Cidofovir.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 225
- Drug.tradename
- Vistide
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AB12
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
- Drug.bioavailability
- complete
- Drug.protein_bound
- <6%
- Drug.elimination_half life
- 2.6 hours (active metabolites: 15–65 hours)
- Drug.excretion
- renal The above pharmacokinetic parameters are measured for cidofovir used in conjunction with probenecid.
via Wikipedia infobox
Chemical data
- Formula
- C8H14N3O6P
- Molecular weight
- 279.19 g/mol
- IUPAC name
- [(2S)-1-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid
- SMILES
- C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O
- InChIKey
- VWFCHDSQECPREK-LURJTMIESA-N
- XLogP
- -3.6
- Polar surface area
- 146 Ų
- H-bond donors
- 4
- H-bond acceptors
- 6
- Formal charge
- 0
via PubChem
Research
2,555 papers- Cidofovir.Drugs · 1996
- Cidofovir.Archives of ophthalmology (Chicago, Ill. : 1960) · 1997
- Cidofovir in the Management of Non-Genital Warts: A Review.Journal of drugs in dermatology : JDD · 2023
- Cidofovir.The AIDS reader · 1999
- Intralesional cidofovir vs. bevacizumab for recurrent respiratory papillomatosis: a systematic review and indirect meta-analysis.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
via PubMed
~3 min read
Encyclopedic overview
12 sectionsContents
- Medical use
- DNA virus
- Other
- Administration
- Side effects
- Contraindications
- Interactions
- Mechanism of action
- History
- Synthesis
- See also
- References
{{Infobox drug | verifiedrevid = 477165826 | IUPAC_name = ({[(S)-1-(4-amino-2-oxo-1,2-dihydropyrimidin-1-yl)-3-hydroxypropan-2-yl]oxy}methyl)phosphonic acid | image = Cidofovir.svg | image_class = skin-invert-image | width = 225
| tradename = Vistide | Drugs.com = | pregnancy_AU = D | routes_of_administration = Intravenous | ATC_prefix = J05 | ATC_suffix = AB12 | ATC_supplemental =
Excerpted from Wikipedia’s “cidofovir” article, available under the CC BY-SA 4.0 licence.